In Stock, Ready to Ship!
$240.00
99% Pure | USA Finished | Multi DoseSurvodutide Peptide 12 mg is a dual-agonist research compound that acts on GLP-1 and glucagon receptors, making it a candidate for studies of metabolic receptor signalling pathways. Researchers are exploring Survodutide for its two-pathway profile, which differs from single-target GLP molecules. For research use only.
In Stock, Ready to Ship!
Described in published literature as a dual receptor agonist, distinct from single-agonist compounds.
Referenced in published studies of GLP-1 receptor signalling pathways.
Cited in published preclinical studies examining hepatic lipid pathways.
Referenced in preclinical literature examining lipid metabolism.
Cited in published studies examining glucose-related signalling pathways.
Referenced in literature examining glucagon receptor activity.
Survodutide is a dual agonist peptide under scientific investigation. It targets both GLP-1 (glucagon-like peptide-1) and glucagon receptors, placing it within the GLP class of research peptides. Originally developed by Boehringer Ingelheim, it is a hybrid molecule combining incretin and glucagon receptor signalling.
Survodutide appears in preclinical and early clinical literature examining metabolic signalling pathways. Real Peptides supplies Survodutide as a research reagent for laboratory use only — not for human consumption or therapeutic use.
Survodutide appears in published research literature on metabolic signalling. Reasons researchers include it in experimental protocols:
Supplied for laboratory research use only — not for human consumption or therapeutic use.
Survodutide differs from other GLP-class research peptides by combining glucagon receptor activation with GLP-1 receptor agonism. Published literature describes:
Real Peptides offers high-purity, U.S.-made Survodutide peptide with third-party testing and transparent lab reports included on every product page. Supplied as a research reagent; no physiological effect is claimed or implied.
Survodutide is a synthetic dual GLP-1 and glucagon receptor agonist peptide, originally developed by Boehringer Ingelheim and currently in clinical trials. Real Peptides supplies it as a research reagent for laboratory use only.
Survodutide belongs to the GLP class of research peptides, distinguished by dual receptor activity across GLP-1 and glucagon pathways. Supplied for laboratory research use only.
Yes, it is a next-generation peptide currently in clinical trials and has not yet received FDA approval outside of clinical settings.
Published studies examine Survodutide in the context of metabolic signalling pathways in preclinical models. Supplied as a research reagent; no physiological effect is claimed or implied.
Researchers reference Survodutide in studies of GLP-1 and glucagon receptor signalling. These describe published findings only, not outcomes in humans.
Survodutide is described in the literature as a dual GLP-1 and glucagon receptor agonist, whereas most GLP-class research peptides act on a single receptor pathway.
Real Peptides offers U.S.-made Survodutide for research with full lab reports and high purity.
Survodutide dosage depends on the research model; consult peer-reviewed studies for guidance.
Yes. Research designs have paired Survodutide with Cagrilintide or SLU-PP-332 in co-study protocols.
Published literature covering Survodutide examines GLP-1 and glucagon receptor signalling and related metabolic pathways in preclinical models. These describe published findings only. Real Peptides supplies Survodutide strictly for laboratory research use — not for human consumption or therapeutic use.
Related GLP-1 agonists include Tirzepatide, Semaglutide, and Mazdutide.
Published literature describes Survodutide binding to GLP-1 and glucagon receptors. Supplied as a research reagent; no physiological effect is claimed or implied.
Typically administered subcutaneously in preclinical studies.
99% purity, third-party tested with full lab transparency on product pages.
Don't hestitate to contact us
